Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NHERF1 | O14745 | 2/20 | 0.52 |
| ▸ | PYGL | P06737 | 2/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
| ▸ | GUSB | P08236 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28082015 | 0.88 | MAOA (0.59) | PYGLHRH4MEN1KMT2APOLB | |
| SCHEMBL6019366 | 0.88 | POLB (0.64) | NHERF1HRH4MEN1KMT2APOLB | |
| SCHEMBL1260652 | 0.87 | HRH4 (0.60) | HRH4MEN1KMT2APOLBLMNA | |
| SCHEMBL1156515 | 0.87 | HRH4 (0.60) | HRH4MEN1KMT2APOLBLMNA | |
| SCHEMBL14301819 | 0.86 | PYGL (0.47) | NHERF1PYGLHRH4MEN1KMT2A | |
| SCHEMBL5675864 | 0.86 | MMP2 (0.51) | HRH4MEN1KMT2APOLBTP53 | |
| SCHEMBL8794605 | 0.86 | HRH4 (0.59) | HRH4MEN1KMT2APOLBLMNA | |
| SCHEMBL5087401 | 0.83 | MMP13 (0.65) | PYGLMEN1KMT2ATP53RAB9A | |
| SCHEMBL5087407 | 0.83 | LEF1 (0.55) | PYGLHRH4MEN1KMT2APOLB | |
| SCHEMBL28081980 | 0.82 | TP53 (0.69) | MEN1KMT2APOLBTP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110280890-A1 | PRODRUGS OF CC-1065 ANALOGS | IMMUNOGEN, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-7906545-B2 | Prodrugs of CC-1065 analogs | IMMUNOGEN INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906545-B2 | Prodrugs of CC-1065 analogs | IMMUNOGEN INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20110008373-A1 | PRODRUGS OF CC-1065 ANALOGS | IMMUNOGEN, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110008373-A1 | PRODRUGS OF CC-1065 ANALOGS | IMMUNOGEN, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| EP-1492526-B1 | CONJUGATED PRODRUGS OF CC-1065 ANALOGS | IMMUNOGEN INC (US) | 2010-06-16 | — | — | EP | disclosed |
| US-7655660-B2 | Antitumor antibiotic; water solubility, stability; N-[2-{(1-chloromethyl)-1,2-dihydro-5-[(4-methylpiperazino)carbonyloxy]-3H-benz(e)indol-3-yl}carbonyl]-1H-indol-5-yl]-5-[(3-methyldithio-1-oxopropyl)-amino]-1H-indole-2-carboxamide | IMMUNOGEN INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655660-B2 | Antitumor antibiotic; water solubility, stability; N-[2-{(1-chloromethyl)-1,2-dihydro-5-[(4-methylpiperazino)carbonyloxy]-3H-benz(e)indol-3-yl}carbonyl]-1H-indol-5-yl]-5-[(3-methyldithio-1-oxopropyl)-amino]-1H-indole-2-carboxamide | IMMUNOGEN INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655661-B2 | Prodrugs of CC-1065 analogs | IMMUNOGEN INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655661-B2 | Prodrugs of CC-1065 analogs | IMMUNOGEN INC. (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1492766-A1 | IMPROVED CC-1065 ANALOG SYNTHESIS | Immunogen, Inc. (US) | 2005-01-05 | — | — | EP | disclosed |
| EP-1492526-A2 | IMPROVED PRODRUGS OF CC-1065 ANALOGS | Immunogen, Inc. (US) | 2005-01-05 | — | — | EP | disclosed |
| US-6756397-B2 | SUCH AS (S)-N-(2-((1-CHLOROMETHYL)-1,2-DIHYDRO-5-((4-METHYLPIPERAZINO)CARBONYLOXY) -3H-BENZ(E) INDOL-3-YL)CARBONYL)-1H-INDOL-5-YL)-5-((3-METHYLDITHIO-1-OXOPROPYL)-AMINO) -1H-INDOLE-2-CARBOXAMIDE; ENHANCED WATER SOLUBILITY AND STABILITY | IMMUNOGEN, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20040109867-A1 | Prodrugs of CC-1065 analogs | IMMUNOGEN INC. | 2004-06-10 | — | — | US | disclosed |
| WO-2003086318-A2 | IMPROVED PRODRUGS OF CC-1065 ANALOGS | IMMUNOGEN, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030199519-A1 | Prodrugs of CC-1065 analogs | IMMUNOGEN INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2003087055-A1 | IMPROVED CC-1065 ANALOG SYNTHESIS | IMMUNOGEN, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030195365-A1 | CC-1065 analog synthesis | IMMUNOGEN INC. | 2003-10-16 | — | — | US | disclosed |
| US-6586618-B1 | Amination 1,3-dihydoxynaphthalene, then blocking, iodination, alkylation, cyclization and deblocking to give (5-hydroxy-3-amino-1-(S)-(chloromethyl)-1,2-dihydro-3H-benz(e)indole), used as chemical intermediates of antitumor agents | IMMUNOGEN INC. | 2003-07-01 | — | — | US | disclosed |
| US-6534660-B1 | Halogenation, alkylation and ring-closure of protected 2-amino-4-hydroxynaphthalene under suitable conditions to provide desired racemate, isolating (-) isomer, removing protecting groups | IMMUNOGEN, INC. | 2003-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280890-A1 | PRODRUGS OF CC-1065 ANALOGS | CASP5, SENP5, CWC15 | NHERF1 2296/4885PYGL 1660/4885HRH4 2186/4885 |
| US-20030199519-A1 | Prodrugs of CC-1065 analogs | CASP5, DNPEP, PRCP | NHERF1 3653/4885PYGL 386/4885HRH4 3330/4885 |
| US-20110008373-A1 | PRODRUGS OF CC-1065 ANALOGS | CASP5, DNPEP, PRCP | NHERF1 3653/4885PYGL 386/4885HRH4 3330/4885 |
| US-20040109867-A1 | Prodrugs of CC-1065 analogs | CASP5, DNPEP, PRCP | NHERF1 3653/4885PYGL 386/4885HRH4 3330/4885 |
| US-20030195365-A1 | CC-1065 analog synthesis | DCUN1D5, DCUN1D1, DBN1 | NHERF1 1517/4885PYGL 4810/4885HRH4 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.